Jubilant Pharmova appoints Jaidev Rajpal as head of Generics business

15 Sep 2022 , 09:14 AM

Jubilant Pharmova Limited, an integrated global pharmaceutical company, announced that Jaidev Rajpal would join the company as Head of Generics business on October 11, 2022.

Jaidev has been named Managing Director and CEO of the Company’s wholly-owned subsidiary, Jubilant Generics Limited, which is involved in the development, production, and distribution of formulations to US and non-US markets, as well as the India Branded Pharmaceuticals business.

Jaidev has more than two decades of expertise in management consulting, advising, and reforming top generic pharmaceutical firms in India and throughout the world.

He has a track record of successfully completing corporate transformation initiatives. He comes to Jubilant from McKinsey & Company, where he is a Partner in the Pharmaceuticals and Life Sciences group.

The hiring of Jaidev will assist the Company in modernizing its Generics business via commercial and operational excellence, as well as portfolio and R&D rebalancing.

Pramod Yadav, who will continue to be the CEO of the Specialty Pharma (Radiopharma and Allergy Immunotherapy) and CDMO-Sterile Injectables companies, will hand over the Generics business to Jaidev.

At around 9.17 AM, Jubilant Pharmova was trading 0.48% higher at Rs333.05, against previous close of Rs331.45 on NSE.

For feedback and suggestions, write to us at [e-mail]